- The USPTO has issued a notice of allowance to Aurinia Pharmaceuticals (NASDAQ:AUPH) for patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”.
- The allowed claims cover a method of modifying the dose of voclosporin in patients with lupus nephritis (LN) based on patient specific pharmacodynamic parameters.
- The U.S. patent is expected to be issued with a term extending to December 2037.
- The Company has also filed for protection of this subject matter under the Patent Cooperation Treaty.
- Shares are up 3% premarket.